
The first Ebola vaccine has been administered to 20 healthy adults in clinical trials in the United States, researchers.
The trial vaccine was developed through collaboration of the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, and Okairos, a Swiss-Italian biotech company recently acquired by the pharmaceutical company GlaxoSmithKline, German Press Agency dpa reported.
The vaccine was first successfully tested on monkeys ahead of the 48-week trial on human participants between the ages of 18 and 50.
There is no danger that the participants can become infected with the disease, NIAID said.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor